Many people with moderate or severe pulmonary sarcoidosis — the target market for the investigational therapy efzofitimod — are highly burdened by the disease and are dependent on corticosteroids that […] The post Presentations highlight efzofitimod’s potential for pulmonary sarcoidosis appeared first on Sarcoidosis News.| Sarcoidosis News – The Web's Daily Resource for Sarcoidosis News
Phase III clinical trials are a pivotal milestone in the journey of developing new treatments for PTSD (Post-Traumatic Stress Disorder). These trials not only confirm the efficacy and safety of potential therapies but also lay the groundwork for regulatory approval and widespread clinical use. In this blog, we’ll dive into what Phase III trials entail, … Understanding Phase III Trials for PTSD: What Are the Next Steps? Read More »| Princeton Medical Institute